Key result
Intracoronary tirofiban significantly improved successful reperfusion (32% vs 10%) and reduced in-hospital MACE (19% vs 36%, P=0.013) in STEMI patients undergoing primary PCI.
Why the study?
Does intracoronary tirofiban improve TIMI flow grade and reduce in-hospital MACE in patients with STEMI undergoing primary PCI?
RCT (n=162)
randomized
Does intracoronary tirofiban improve TIMI flow grade and reduce in-hospital MACE in patients with STEMI undergoing primary PCI?
Absolute Event Rate: 32% vs 10%
Intracoronary tirofiban improves acute TIMI flow and reduces in-hospital MACE in STEMI patients with no-reflow during primary PCI.
Supports intracoronary tirofiban in STEMI primary PCI; extends randomized evidence for targeted GP IIb/IIIa inhibitor delivery.
We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Consecutive patients (n = 162) were randomized into 2 groups based on whether intracoronary tirofiban was administered. After the administration of intracoronary tirofiban, thrombolysis in myocardial infarction (TIMI) flow grade significantly increased (P < .001) and successful reperfusion was achieved in 26 (32%) patients. In the placebo group, however, after the administration of intracoronary placebo the TIMI flow grade did not change (P = .070), and successful reperfusion was achieved only in 8 (10%) patients. In-hospital major adverse cardiac events (MACE) were significantly lower in the tirofiban group (36% vs 19%, P = .013). Intracoronary administration of tirofiban significantly improves TIMI flow grade and is associated with a lower in-hospital rate of MACE.
No takes yet. Share an insight, caveat, or question.
Akpek et al. (2014) conducted an RCT in ST-segment elevated myocardial infarction with no-reflow phenomenon (n=162). Intracoronary tirofiban vs. Intracoronary placebo was evaluated on Successful reperfusion. Intracoronary tirofiban significantly improved successful reperfusion (32% vs 10%) and reduced in-hospital MACE (19% vs 36%, P=0.013) in STEMI patients undergoing primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: